Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review

Aims: Increasing evidence for benefit of early detection of cystic fibrosis related diabetes (CFRD) coupled with limitations of current diagnostic investigations has led to interest and utilisation of continuous glucose monitoring (CGM). We conducted a systematic review to assess current evidence on...

Full description

Bibliographic Details
Main Authors: Shanal Kumar, Michael Pallin, Georgia Soldatos, Helena Teede
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Journal of Clinical & Translational Endocrinology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214623722000138
_version_ 1811188618496049152
author Shanal Kumar
Michael Pallin
Georgia Soldatos
Helena Teede
author_facet Shanal Kumar
Michael Pallin
Georgia Soldatos
Helena Teede
author_sort Shanal Kumar
collection DOAJ
description Aims: Increasing evidence for benefit of early detection of cystic fibrosis related diabetes (CFRD) coupled with limitations of current diagnostic investigations has led to interest and utilisation of continuous glucose monitoring (CGM). We conducted a systematic review to assess current evidence on CGM compared to reference standard oral glucose tolerance test for the detection of dysglycemia in people with cystic fibrosis without confirmed diabetes. Methods: MEDLINE, Embase, CENTRAL, Evidence-Based Medicine Reviews, grey literature and six relevant journals were searched for studies published after year 2000. Studies reporting contemporaneous CGM metrics and oral glucose tolerance test results were included. Outcomes on oral glucose tolerance tests were categorised into a) normal, b) abnormal (indeterminate and impaired) or c) diabetic as defined by American Diabetes Association criteria. CGM outcomes were defined as hyperglycemia (≥1 peak sensor glucose ≥ 200 mg/dL), dysglycemia (≥1 peak sensor glucose ≥ 140–199 mg/dL) or normoglycemia (all sensor glucose peaks < 140 mg/dL). CGM hyperglycemia in people with normal or abnormal glucose tolerances was used to define an arbitrary CGM-diagnosis of diabetes. The Quality Assessment of Diagnostic Accuracy Studies tool was used to assess risk of bias. Primary outcome was relative risk of an arbitrary CGM-diagnosis of diabetes compared to the oral glucose tolerance test. Results: We identified 1277 publications, of which 19 studies were eligible comprising total of 416 individuals with contemporaneous CGM and oral glucose tolerance test results. Relative risk of an arbitrary CGM-diagnosis of diabetes compared to oral glucose tolerance test was 2.92. Studies analysed were highly heterogenous, prone to bias and inadequately assessed longitudinal associations between CGM and relevant disease-specific sequela. Conclusions: A single reading > 200 mg/dL on CGM is not appropriate for the diagnosis of CFRD. Prospective studies correlating CGM metrics to disease-specific outcomes are needed to determine appropriate cut-points.
first_indexed 2024-04-11T14:23:01Z
format Article
id doaj.art-227edfc117f14c4cac0ef093a29e4227
institution Directory Open Access Journal
issn 2214-6237
language English
last_indexed 2024-04-11T14:23:01Z
publishDate 2022-12-01
publisher Elsevier
record_format Article
series Journal of Clinical & Translational Endocrinology
spelling doaj.art-227edfc117f14c4cac0ef093a29e42272022-12-22T04:19:00ZengElsevierJournal of Clinical & Translational Endocrinology2214-62372022-12-0130100305Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic reviewShanal Kumar0Michael Pallin1Georgia Soldatos2Helena Teede3Monash Centre for Health Research and Implementation, Monash University; Diabetes and Vascular Medicine Unit, Monash HealthMonash Lung and Sleep, Monash HealthMonash Centre for Health Research and Implementation, Monash University; Diabetes and Vascular Medicine Unit, Monash HealthMonash Centre for Health Research and Implementation, Monash University; Diabetes and Vascular Medicine Unit, Monash Health; Corresponding author at: Monash Centre for Health Research and Implementation, Level 1, 43-51 Kanooka Grove, Clayton, VIC 3168, Australia.Aims: Increasing evidence for benefit of early detection of cystic fibrosis related diabetes (CFRD) coupled with limitations of current diagnostic investigations has led to interest and utilisation of continuous glucose monitoring (CGM). We conducted a systematic review to assess current evidence on CGM compared to reference standard oral glucose tolerance test for the detection of dysglycemia in people with cystic fibrosis without confirmed diabetes. Methods: MEDLINE, Embase, CENTRAL, Evidence-Based Medicine Reviews, grey literature and six relevant journals were searched for studies published after year 2000. Studies reporting contemporaneous CGM metrics and oral glucose tolerance test results were included. Outcomes on oral glucose tolerance tests were categorised into a) normal, b) abnormal (indeterminate and impaired) or c) diabetic as defined by American Diabetes Association criteria. CGM outcomes were defined as hyperglycemia (≥1 peak sensor glucose ≥ 200 mg/dL), dysglycemia (≥1 peak sensor glucose ≥ 140–199 mg/dL) or normoglycemia (all sensor glucose peaks < 140 mg/dL). CGM hyperglycemia in people with normal or abnormal glucose tolerances was used to define an arbitrary CGM-diagnosis of diabetes. The Quality Assessment of Diagnostic Accuracy Studies tool was used to assess risk of bias. Primary outcome was relative risk of an arbitrary CGM-diagnosis of diabetes compared to the oral glucose tolerance test. Results: We identified 1277 publications, of which 19 studies were eligible comprising total of 416 individuals with contemporaneous CGM and oral glucose tolerance test results. Relative risk of an arbitrary CGM-diagnosis of diabetes compared to oral glucose tolerance test was 2.92. Studies analysed were highly heterogenous, prone to bias and inadequately assessed longitudinal associations between CGM and relevant disease-specific sequela. Conclusions: A single reading > 200 mg/dL on CGM is not appropriate for the diagnosis of CFRD. Prospective studies correlating CGM metrics to disease-specific outcomes are needed to determine appropriate cut-points.http://www.sciencedirect.com/science/article/pii/S2214623722000138Continuous glucose monitoringCystic fibrosisDiabetesDiagnosis
spellingShingle Shanal Kumar
Michael Pallin
Georgia Soldatos
Helena Teede
Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review
Journal of Clinical & Translational Endocrinology
Continuous glucose monitoring
Cystic fibrosis
Diabetes
Diagnosis
title Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review
title_full Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review
title_fullStr Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review
title_full_unstemmed Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review
title_short Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review
title_sort comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic fibrosis a systematic review
topic Continuous glucose monitoring
Cystic fibrosis
Diabetes
Diagnosis
url http://www.sciencedirect.com/science/article/pii/S2214623722000138
work_keys_str_mv AT shanalkumar comparisonofcontinuousglucosemonitoringtoreferencestandardoralglucosetolerancetestforthedetectionofdysglycemiaincysticfibrosisasystematicreview
AT michaelpallin comparisonofcontinuousglucosemonitoringtoreferencestandardoralglucosetolerancetestforthedetectionofdysglycemiaincysticfibrosisasystematicreview
AT georgiasoldatos comparisonofcontinuousglucosemonitoringtoreferencestandardoralglucosetolerancetestforthedetectionofdysglycemiaincysticfibrosisasystematicreview
AT helenateede comparisonofcontinuousglucosemonitoringtoreferencestandardoralglucosetolerancetestforthedetectionofdysglycemiaincysticfibrosisasystematicreview